Doug Hampton

Excellent 12-Month Results from SELUTION SFA Trial Presented at JET

by

GENEVA, May 31, 2023 /PRNewswire/ — 12-month results from the SELUTION SFA trial have been presented at the Japan Endovascular Treatment (JET) Conference in Tokyo. The objective of this study was to assess the safety and efficacy of SELUTION SLR™, MedAlliance’s novel sirolimus-eluting balloon, for endovascular therapy of de novo and non-stented restenotic lesions in the … Read more

THINK Surgical’s TMINI Miniature Robotic System developed with Sagentia Innovation gains FDA 510(k) clearance

by

CAMBRIDGE, England, May 31, 2023 /PRNewswire/ — THINK Surgical, Inc. recently announced that its TMINI™ Miniature Robotic System has received 510(k) clearance from the U.S. Food and Drug Administration (FDA). THINK Surgical chose R&D consultancy Sagentia Innovation, a market-leading advanced surgical robotics developer, to support key aspects of the TMINI system’s development. THINK Surgical’s TMINI(TM) … Read more

Increase in share capital in INVISIO due to exercise of stock options

by

STOCKHOLM, May 31, 2023 /PRNewswire/ — Due to exercise of outstanding stock options issued to secure delivery of shares under the INVISIO employee stock option program 2020/2023, INVISIO’s share capital has increased from SEK 45,048,694 to SEK 45,590,194. This is an increase of SEK 541,500, distributed among 541,500 new shares. The total number of shares and … Read more

SNIPR Biome reports positive clinical interim results for groundbreaking, first-in-human, CRISPR-based microbial gene therapy

by

SNIPR001 demonstrates proof of principle in reducing E. coli levels in the human gastrointestinal tract SNIPR001 is a novel CRISPR-Cas therapeutic, selectively targeting antibiotic-resistant E. coli which can cause life-threatening infections in vulnerable hematological cancer patients Future studies needed to evaluate the impact of SNIPR001 on reducing the rate of E. coli infections in high-risk … Read more

Cambrex Celebrates Grand Opening of New Q1 Scientific Facility in Belgium and Secures First Stability Storage Commercial Agreement

by

EAST RUTHERFORD, N.J, May 31, 2023 /PRNewswire/ — Cambrex, a leading global contract development and manufacturing organization (CDMO) providing drug substance, drug product, and analytical services across the entire drug lifecycle, yesterday celebrated the grand opening of its new Q1 Scientific facility in Belgium and announced the signing of a new commercial agreement with QUALIblood, … Read more

Anticoagulants Market by Route of Administration to grow by USD 18,091.94 million from 2023 to 2027; The increase in hip and knee surgeries is driving the market growth

by

NEW YORK, May 31, 2023 /PRNewswire/ — The anticoagulants market size is forecast to increase by USD 18,091.94 million from 2023 to 2027, at a CAGR of 8.42%, according to the recent market study by Technavio. The growth of the market will be driven by the Introduction of novel oral anticoagulants, Growing prevalence of coagulation disorders, and Increase … Read more

SK bioscience reçoit une autorisation de mise sur le marché de la MHRA du Royaume-Uni pour son vaccin contre la COVID-19

by

L’autorisation de mise sur le marché accordé au vaccin contre la COVID-19 de SK bioscience par la MHRA sera valable au Royaume-Uni. SKYCovion™ est le tout premier vaccin au monde mis au point à l’aide de RoseTTAFold, un logiciel utilisant l’apprentissage profond. SK bioscience a présenté une demande d’inscription à la liste des utilisations d’urgence … Read more

True or false. Does gout affect men more?

by

the essential The attack of gout is manifested by inflammatory flare-ups in the joints. This common chronic disease is often known to affect men more than women. What is it really ? How to prevent these extremely painful attacks? The point with a rheumatologist. A gout attack is an inflammation of the joints due to … Read more